Egypt's parliament passes unified real estate ID law    EGP stable vs. US dollar in early trade    Egypt's El-Khatib: Govt. keen on boosting exports    Eygpt's El-Sherbiny directs new cities to brace for adverse weather    Egypt's investment authority GAFI hosts forum with China to link business, innovation leaders    CBE governor meets Beijing delegation to discuss economic, financial cooperation    Cabinet approves establishment of national medical tourism council to boost healthcare sector    Egypt's Gypto Pharma, US Dawa Pharmaceuticals sign strategic alliance    Egypt's Foreign Minister calls new Somali counterpart, reaffirms support    "5,000 Years of Civilizational Dialogue" theme for Korea-Egypt 30th anniversary event    Egypt's Al-Sisi, Angola's Lourenço discuss ties, African security in Cairo talks    Egypt's Al-Mashat urges lower borrowing costs, more debt swaps at UN forum    Two new recycling projects launched in Egypt with EGP 1.7bn investment    Egypt's ambassador to Palestine congratulates Al-Sheikh on new senior state role    Egypt's Health Min. discusses childhood cancer initiative with WHO    Egypt pleads before ICJ over Israel's obligations in occupied Palestine    Egypt's EDA discusses local pharmaceutical manufacturing with Bayer    Sudan conflict, bilateral ties dominate talks between Al-Sisi, Al-Burhan in Cairo    Cairo's Madinaty and Katameya Dunes Golf Courses set to host 2025 Pan Arab Golf Championship from May 7-10    Egypt expresses condolences to Canada over Vancouver incident    Egypt's Ministry of Health launches trachoma elimination campaign in 7 governorates    EHA explores strategic partnership with Türkiye's Modest Group    Between Women Filmmakers' Caravan opens 5th round of Film Consultancy Programme for Arab filmmakers    Fourth Cairo Photo Week set for May, expanding across 14 Downtown locations    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Ancient military commander's tomb unearthed in Ismailia    Egypt's FM inspects Julius Nyerere Dam project in Tanzania    Egypt's FM praises ties with Tanzania    Egypt to host global celebration for Grand Egyptian Museum opening on July 3    Ancient Egyptian royal tomb unearthed in Sohag    Egypt hosts World Aquatics Open Water Swimming World Cup in Somabay for 3rd consecutive year    Egyptian Minister praises Nile Basin consultations, voices GERD concerns    49th Hassan II Trophy and 28th Lalla Meryem Cup Officially Launched in Morocco    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Paris Olympics opening draws record viewers    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Pfizer Beats Sales and Profit Forecasts, Mum on Future Deals
Published in Amwal Al Ghad on 29 - 10 - 2014

Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).
The largest U.S. drugmaker on Tuesday said it had earned $2.67 billion, or 42 cents per share, in the third quarter. That compared with $2.59 billion, or 39 cents per share, a year earlier.
Excluding special items, Pfizer earned 57 cents per share. Analysts on average expected 55 cents, according to Thomson Reuters I/B/E/S.
Sales fell 2 percent to $12.36 billion, hurt by generic competition and expiration of a longstanding deal with Amgen Inc (AMGN.O) to co-market its Enbrel arthritis drug. But they topped Wall Street expectations of $12.24 billion.
Pfizer tightened its full-year earnings forecast to between $2.23 and $2.27 per share from its prior outlook of $2.20 to $2.30.
The company officially gave up its six-month pursuit of AstraZeneca after its final $118 billion bid was rejected on May 26. It had hoped to base the combined company in Britain, which has lower taxes than the United States, a maneuver called tax inversion.
Under UK takeover rules, Pfizer can make another run at AstraZeneca late next month, but the company did not mention its intentions in Tuesday's earnings report.
U.S. drugmaker AbbVie (ABBV.N) two weeks ago gave up its $55 billion quest to buy Dublin drugmaker Shire, another tax-inversion deal, because of new U.S. Treasury tax rules that made the deal less attractive.
"Now that (AbbVie) has canceled its deal, it's less likely that Pfizer will move ahead" with its own attempt at AstraZeneca, said Edward Jones analyst Ashtyn Evans.
But given Pfizer's predicted lack of growth over the next few years because of patent expirations, Evans said Pfizer "will still have to do something, like breaking up the company or making a big acquisition."
In the next four years, generic rivals will challenge blockbuster Pfizer products such as painkiller Celebrex, nerve pain treatment Lyrica and anti-impotence drug Viagra. The three drugs, with combined annual sales of almost $10 billion, generate about 20 percent of current company sales.
Lyrica sales jumped 16 percent to $1.32 billion in the quarter, while Viagra sales fell 7 percent to $427 million due to generic competition in Europe. Sales of Celebrex, which goes generic in the United States in December, rose 2 percent to $764 million.
Pfizer Chief Executive Ian Read on Tuesday said the company would rely on "operational and financial efficiencies and remain opportunistic regarding business development." The company stressed that its board last week had authorized a new $11 billion share repurchase program over time.
Pfizer shares rose 3 cents to $29.06 in premarket trading.
Source: Reuters


Clic here to read the story from its source.